linjc16/ctgov huggingface dataset:
Videoscope Guided Flexible LMA Insertion

Study Overview
=================
Brief Summary
-----------------
Laryngeal Mask Airway Flexible (LMA Flexible) is useful in various surgery because of its unique design. The flexometallic tube allows it could be used in head and neck related surgery but also make insertion more difficult. The ideal position of LMA Flexible is important because in most case, the surgery requiring LMA Flexible allows movements of the stem or patient's head during operation without dislodgement of LMA Flexible. Several studies have examined different techniques like assisting LMA Flexible with rigid introducers or lifting epiglottis with direct laryngoscope. But there is no study using videolaryngoscope (VL) for LMA Flexible insertion. The investigator hypothesized that McGrath(McGRATH™ MAC video laryngoscope;Aircraft Medical Ltd, UK.), one kind of the VL, assisted insertion would increase the success rate of LMA Flexible insertion by lifting epiglottis and securing a view while LMA Flexible is seated. The aim of this study was to investigate the efficacy of the McGrath VL assisted insertion of LMA Flexible compared with the standard method of digital manipulation technique in regard to the ideal anatomical position and sealing pressure in anesthetized adult patients.

Official Title
-----------------
Videoscope Guided Flexible LMA Insertion : Comparison With Blind Insertion

Conditions
-----------------
Ideal Position of LMA Flexible

Intervention / Treatment
-----------------
* Device: Mcgrath
* Device: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA (American society of anesthesiologist) physical status classification system I and II, scheduled to elective general anesthesia with the use of LMA Exclusion Criteria: suspected difficult airway a history of a recent upper airway tract infection gastroesophageal reflux body mass index > 30 kg/m2

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control group<br> | Device: Control<br>* Digital manipulation technique of LMA flexible insertion<br>|
| Experimental: McGrath group<br> | Device: Mcgrath<br>* McGrath assisted insertion of LMA flexible<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ideal positioning rate of LMA flexible |  | 3 minute after LMA flexible insertion |
Disulfiram as a Modulator of Amyloid Precursor Protein-processing

Study Overview
=================
Brief Summary
-----------------
A causal therapeutic approach for treatment of Alzheimer's disease has not been established so far. The protein ADAM10 represents a promising target for an A-beta peptide preventing strategy. Treatment of human neuronal cells with Disulfiram, a drug which is used in clinical routine for recrudescence prevention of alcohol dependency, revealed an increased expression of ADAM10. This finding indicates a neuroprotective potential of Disulfiram. The investigators' research purpose aims at the verification of the results obtained in cell culture experiments in the human organism. Therefore, include alcohol addicted patients were included, which take the drug Disulfiram for recrudescence prevention, in our study. Patients are recruited from the patient-collective of the University Medical Center Mainz and the Central Institute for Mental Health Mannheim. Blood samples (max. 5 ml) are taken from the participants before the intake of Disulfiram and about two weeks after treatment. Demographic data are collected (such as age or onset of addiction). Gene expression is analyzed via reverse transcription polymerase chain reaction(RT-PCR) from blood cell-derived messenger ribonucleic acid (mRNA).

Official Title
-----------------
Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram

Conditions
-----------------
Alcohol Addiction

Intervention / Treatment
-----------------
* Drug: Disulfiram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ambulant or stationary patients, which receive Disulfiram for recrudescence prevention Exclusion Criteria: Diagnosed Alzheimer's dementia Previous Disulfiram treatment less than four weeks before baseline blood collection

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| expression of ADAM10 | expression of ADAM10 in the collected blood samples measured by quantitation of the mRNA amount using RealTime-RT-PCR. | August 2016 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
APP-processing, Disulfiram, ADAM10, Alzheimer's disease, blood
Effects of AN69 ST Hemofilter on Coagulation During Continuous Renal Replacement Therapy in Critically Ill

Study Overview
=================
Brief Summary
-----------------
Compared with AN69 hemofilter, AN69 ST hemofilter may prolong the time of hemofilter and decrease the quantity of heparin during continuous renal replacement therapy in critically ill.

Official Title
-----------------
Effects of AN69 ST Hemofilter on Coagulation During Continuous Renal Replacement Therapy in Critically Ill

Conditions
-----------------
Critically Ill, Acute Kidney Injury, Septic Shock

Intervention / Treatment
-----------------
* Device: AN 69 ST hemofilter
* Device: AN 69 hemofilter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age> 18 years old admitted to ICU and need CRRT anticipated survival time >72h Exclusion Criteria: allergy to hemofilter or heparin heparin associated thrombocytopenia pregnancy or lactation using other anticoagulate drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AN 69 ST hemofilter<br>Use AN 69 ST hemofilter during CRRT | Device: AN 69 ST hemofilter<br> <br> |
| Active Comparator: AN 69 hemofilter<br>Use AN 69 hemofilter during CRRT | Device: AN 69 hemofilter<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The using time of hemofilters | The time from the beginning of continuous renal replacement therapy until to the end when continuous renal replacement therapy had to be finished because of clotting or other reasons | 72h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| activated partial thromboplastin time | Heparin will be used according to activated partial thromboplastin time, and the quantity will be recorded. | every 6h from the begining of continuous renal replacement therapy,up to 72h | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemofilter, coagulation, CRRT, critically ill
Obstetric Anaesthesia And Analgesia Month Attributes - International

Study Overview
=================
Brief Summary
-----------------
A national survey of current practices, preferred drug and technique choices for obstetric anesthesia and analgesia in Czech Republic and Slovak Republic.

Detailed Description
-----------------
A one month-long project monitoring an obstetric anesthesia practices in obstetric/anesthesia departments throughout the Czech Republic. Electronic Case Report Form (eCRF) is used to collect data on all obstetric anesthesia procedures in peripartal period and obstetric and anesthesia complications. All consecutive cases in each participating center during the study period are recorded. Each record is related to parturient and contains the following sections: history, form of labour analgesia, type of anesthesia for Cesarean section and anesthesia in third stage of labor.

Official Title
-----------------
A National Survey on Obstetric Anesthesia and Analgesia Care - International

Conditions
-----------------
Obstetric Anesthesia Care

Intervention / Treatment
-----------------
* Procedure: Obstetric anesthesia and analgesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women in labor undergoing anesthesia care Exclusion Criteria: not meeting inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women in labor undergoing anesthesia care<br>Women in labor undergoing anesthesia care | Procedure: Obstetric anesthesia and analgesia<br>* All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A national survey of current practice of obstetric anesthesia and analgesia in Czech Republic and Slovak Republic | Monitoring of all obstetric anesthesia procedures in peripartal period and anesthesia complications: history, form of labour analgesia, type of anesthesia for Cesarean section and anesthesia in third stage of labor. | Parturition period, up to 24 hours after labor | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Types of anesthesia a analgesia in peripartal period | To describe current practice a complications related to peripartal anesthesia care | Parturition period, up to 24 hours after labor |
Role of Hyaluronic Acid in the Prevention of Post-operative Adhesions: a RCT

Study Overview
=================
Brief Summary
-----------------
The objective of study is to determine the effect of hyaluronic acid on the formation of post-operative adhesions. It will be a randomized control trial comparing the product against normal saline.

Official Title
-----------------
Is Hyaluronic Acid Effective in the Prevention of Post-operative Adhesion?

Conditions
-----------------
Post Operative Adhesions

Intervention / Treatment
-----------------
* Drug: Hyaluronic Acid
* Drug: NORMAL SALINE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All consenting patients between the ages of 12-80, who undergo exploratory laparotomy and stoma formation Exclusion Criteria: Previous history of abdominal surgery History of peritoneal dialysis Patients in whom permanent stoma is formed -

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HiB<br>This group will receive the compound for the reduction of adhesions | Drug: Hyaluronic Acid<br> <br> |
| Placebo Comparator: Normal saline<br>This group will just receive normal saline to ensure blinding. | Drug: NORMAL SALINE<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| POST OPERATIVE ADHESIONS TO BE EVALUATED BY LAPAROSCOPY AT THREE MONTHS INTERVAL |  | 3 months |
Learning Curve of VL for Intubation During CPR

Study Overview
=================
Brief Summary
-----------------
This is a clinical study based on analysis of video-clip data of endotracheal intubation (ETI) using videolaryngoscope (VL) and clinical data for cardiopulmonary resuscitation patients between 2012.03.01.-2015.02.28. The purpose of this study is to evaluate the appropriate numbers of VL usages for successful ETI at first attempt during cardiopulmonary resuscitation.

Detailed Description
-----------------
Direct layngoscope (DL) is a basic tool for endotracheal intubation(ETI) during cardiopulmonary resuscitation(CPR). ETI during CPR has higher risks of failure or delayed success with frequent attempts, misplacement of the tube, and prolonged interruptions of chest compressions. The main problems associated with ETI relate to the inherently technical difficulty in using DL. VL have various advantages of fast learning curve and overall success comparing with the DL in non-arrest patients, but there was no known data of learnig curve of successful ETI during CPR. This study tried to estimate the the appropriate numbers of VL usage for successful ETI at first attempt during CPR. So the investigators analyze the success rate, speed, trial number, incidence of complications, and hands-off time of ETI using VL which in real clinical setting. In addition, this study analyze the residency training term, total number of of VL usage using VL at that time.

Official Title
-----------------
Learning Curve of Video-laryngoscope (VL) for First Attempt Successful Endotracheal Intubation During Cardiopulmonary Resuscitation (CPR)

Conditions
-----------------
Cardiopulmonary Arrest

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who suffer sudden cardiac arrest and physician tried ti intubate using viseolaryngoscope. Exclusion Criteria: case of requesting the do-not-attempt resuscitation befor ETI intubated cases before arrival to emergency department physician tried ti intubate using direct-laryngoscope

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| YES or No of successful intubation without complication | endotracheal intubation, hands-off time < 10 seconds, first trial | successful endotracheal intubation with in 60 seconds | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intubation, cardiopulmonary resuscitation, Learning curve, videolaryngoscope
CholGate - The Effect of Alerting Versus on Demand Computer Based Decision Support on Treatment of Dyslipidaemia by General Practitioners

Study Overview
=================
Brief Summary
-----------------
Indirect evidence show alerting physicians with clinical decision support systems (CDSS) seem to change behaviour more than requiring users to actively initiate the system. However, randomized trials comparing these methods in a clinical setting are lacking. In this study we compare the effect of Alerting physicians with a CDSS or actively requiring initiation of CDSS on the adherence of Dutch general practitioners to the Cholesterol guideline of the Dutch college of General Practitioners.

Detailed Description
-----------------
Indirect evidence show alerting physicians with clinical decision support systems (CDSS) seem to change behaviour more than requiring users to actively initiate the system. However, randomized trials comparing these methods in a clinical setting are lacking. In this study we compare the effect of Alerting physicians with a CDSS or actively requiring initiation of CDSS on the adherence of Dutch general practitioners to the Cholesterol guideline of the Dutch college of General Practitioners, using a clinical decsion support system called CholGate. This system has the functionality to provide both Alerting and On-Demand decision support. Users are free to negate the advise provided by the decision support system. The trial will have a cluster randomized structure.

Official Title
-----------------
The Effect of Alerting Versus on Demand Computer Based Decision Support on Treatment of Dyslipidaemia by General Practitioners - The CholGate Randomized Trial

Conditions
-----------------
Decision Support Systems, Clinical

Intervention / Treatment
-----------------
* Device: CholGate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All general practices using only Elias electronic patient records (ISOFT b.V) All patients meeting the screening and treatment criteria of the Dutch college of general practitioners cholesterol guideline Exclusion Criteria: Practices that used paper based records

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: CholGate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of correctly screened patients using anonymous patient record data. |  |  | 
| The percentage of correctly treated patients using anonymous patient record data. |  |  |
Functional Proteomics of Alveolar Macrophages

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to obtain young white blood cells (monocytes) from the investigators donated blood for research into how these cells change into large, mature white blood cells (macrophages) and how smoking causes Chronic Obstructive Pulmonary Disease (COPD).

Detailed Description
-----------------
Our research goal is to identify new targets and strategies to help care for patients with Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic airway inflammatory disorder characterized by a progressive loss of pulmonary function. Mononuclear phagocytes are known to be critically involved in both repair/remodeling and destructive events in COPD. Although smoking is the chief environmental risk factor for COPD, the molecular details responsible for the genesis and progression of smoking-mediated COPD require further investigation. In searching for new knowledge and research strategies for this challenging topic, we have made substantial progress in mononuclear phagocyte proteomics and laid the groundwork for this translational research of COPD.

Official Title
-----------------
Functional Proteomics of Alveolar Macrophages

Conditions
-----------------
COPD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD, smoker COPD, non smoker Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD subjects<br>healthy subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to define AM's pathogenic pathways underlying the development of COPD |  | end of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to determine protein polymorphism(s) that impact genetic susceptibility to COPD |  | end of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AM proteomes will be compared between smokers with and without COPD
A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see how molecules called pharmacological chaperones affect the cells of patients with Pompe disease. The study will last 1 or 2 visits which will include a blood collection, urine collection, and two skin biopsies. Information will also be collected from the medical records about disease history and diagnosis. Patients will not receive any study medication.

Detailed Description
-----------------
The study is designed to evaluate the response of cell lines derived from blood and skin tissue from Pompe patients to pharmacological chaperones. Samples of blood and skin tissue will be obtained to make cell lines that will be used to test pharmacological chaperones. The study will include patients with early and late-onset Pompe disease.

Official Title
-----------------
A Multicenter Study to Evaluate and Characterize the Effects of Pharmacological Chaperones in Cell Lines Derived From Blood and Skin Samples From Patients With Pompe Disease

Conditions
-----------------
Pompe Disease, Glycogen Storage Disease Type II

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female of any age Confirmed diagnosis of Pompe disease (early or late-onset) Clinically stable Written informed consent by subject or legal representative Exclusion Criteria: Other significant disease or otherwise unsuitable for the study, as determined by the investigator
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Group 1 (all subjects) | Other: Observation<br>* Ex vivo administration of AT2220<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate and characterize the effects of pharmacological chaperones on enzyme activity and other markers of disease in cell lines derived from patients with Pompe disease |  | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To study biomarkers associated with Pompe Disease and study the correlation between biomarkers and clinical disease state of patients with Pompe disease |  | 1 week |